* and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]) .
And the conclusion:
> In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.
So yes, it looks to me like at least some of what this Ford study measured was indeed that difference between people with pre-existing conditions dying at a higher rate than people without.
https://www.ijidonline.com/article/S1201-9712(20)30534-8/ful...
* Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%);
by treatment:
* hydroxychloroquine + azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]),
* hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]),
* azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]),
* and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]) .
And the conclusion:
> In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.